

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Fumitoshi ASAI et al.

Serial No. 10/600,266 :

June 20, 2003 Filed

For MEDICINAL COMPOSITIONS

CONTAINING ASPIRIN

Art Unit 1614

Examiner

Confirm. No.: 7488

Customer No.: 01933 Express Mail Mailing Label No.: EL 978 887 755 US Date of Deposit: October 2, 2003

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the

date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450,

Dabee

Alexandria, VA 22313-1450

draine Laraine Dobies

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee, or any other fee

required in connection with this Paper

to Account No. 06-1378.

INFORMATION DISCLOSURE STATEMENT II

COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

In the INFORMATION DISCLOSURE STATEMENT filed June 20, 2003 Form PTO/SB/08B identified all of the references cited in the International Search Report of WO 02/051412 A1 which is the 18month publication of Japanese Patent Application No. 2000-392983 filed December 25, 2000 of which the present application is a Continuation. Because priority is claimed under 35 USC 120 copies were not required. However, for the convenience of the Examiner, copies of these references are enclosed herein.

In addition, enclosed herewith are JP 2000-266780 and JP 2000-205396 (with English translations) that are discussed in the present application on page 2. Also enclosed is JP 2002-145883A (related to EP 1298132A) which is the domestic priority based on JP 2000-205396 and JP 2000-266780, discussed on page 2 of the present application. All of these documents are listed on the enclosed form PTO/SB/08A.

It is requested that the publications be considered with respect to the patentability of the present invention and that an initialed copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B be returned to applicants to indicate that such publications have been considered and made "of record."

Frishauf, Holtz, Goodman & Chick, P.C.
767 Third Ave., 25th Floor New York, NY 10017-2023 Tel. No. (212) 319-4900 Fax No.: (212) 319-5101 MJC/ld

MARSHALL & CHICK Reg. No. 26,853

Respec#fully submitted,

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE

Sheet

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Application Number 10/600,266

Filing Date June 20, 2003

First Named Inventor Fumitoshi ASAI

1614

STATEMENT BY OPLICANT

Group Art Unit

Examiner Name

of 2 Attorney Docket Number 03337C/HG

U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No¹	Document Number	Kind Code²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
			!			
				-0 / 2 %		

FOREIGN PATENT DOCUMENTS

Exam Inits	Cite No¹	Offc'	Document Number4	Kind Code⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
		JP	6-41139			02-15-1994		*
		EP	0 542 411 A2		Ube Ind. Ltd.	05-19-1993		
		JP	2000-266780	1				**
		JP	2000-205396					**
		JР	2002-145883	1		05-22-2002		
		EP	1 298 132 A1	1		04-02-2003		***
		1					11 00041	
Evami	ner	•		-	Date			

Examiner Signature Date Considered

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED: October 2, 2003

- * Patent Family Member of EP 0 542 411 A2
- ** English language translation
- ***Patent Family Member of EP 1 298 132 A1

^{&#}x27;Unique citation designation number. 'See kinds of U.S. Patent Documents.' Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.' Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Place a check here if English translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO					A/PTO	Application Number 10/600,266				
INFORMATION DISCLOSURED CO.						Filing Date		June 20, 2003		
						First Name	d Inventor	Fumitoshi ASAI		
			(00	T 0 2 2003 3	Group Art	Unit	1614		
			·	AND	WE THADENE	Examiner N	ame			
Sheet		2		of	2	Attorney D	ocket Number	03337C/HG		
				OTHER	DOCUMENTS	- NON-PATENT LITERATURE DOCUMENTS				
Examiner Cite			Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published					T^2		
	of ADE of 144				SUGIDACHI et al., "The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties", British Journal of Pharmacology, 2000, Vol. 209, No. 7, pages 1439 to ATABASE CA on STN, AN.133:187474, ASAI, Fumitoshi et					
			al., CS-747, a new platelet ADP receptor antagonist Annual Report of Sankyo Research Laboratories, 1999, Vol. 51, pages 1 to 44, abstract							
	Y		SANIABADI AR et al., "Effect of dipyridamole alone an in combination with aspirin on whole blood platelet aggregation, PGI2 generation, and red cell deformability ex vivo in man", Cardiovascular Research, 1991, Vol. 25, No. 3, pages 177 to 183							
Examiner Signature						Date Considered				

^{*} EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED: October 2, 2003

 $^{^1}$ Unique citation designation number. 2 Place a check here if English translation is attached.